Waters has announced that at the end of February 2009, its Board of Directors authorized the company to repurchase up to $500 million of its outstanding common shares over the next 24 months.
Waters has announced that at the end of February 2009, its Board of Directors authorized the company to repurchase up to $500 million of its outstanding common shares over the next 24 months.
A previous $500 million share repurchase program which had been authorized in February 2007 has expired, but was described by the company as “substantially completed”.
Purchases will be made through open market transactions, subject to market conditions and trading restrictions.
For more information about Waters, visit the company’s website at www.waters.com
LC–MS/MS-Based System Used to Profile Ceramide Reactions to Diseases
April 26th 2024Scientists from the University of Córdoba in Córdoba, Spain recently used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to comprehensively profile human ceramides to determine their reactions to diseases.
High-Throughput 4D TIMS Method Accelerates Lipidomics Analysis
April 25th 2024Ultrahigh-pressure liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) had been previously proposed for untargeted lipidomics analysis, but this updated approach was reported by the authors to reduce run time to 4 min.
LC–MS/MS-Based System Used to Profile Ceramide Reactions to Diseases
April 26th 2024Scientists from the University of Córdoba in Córdoba, Spain recently used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to comprehensively profile human ceramides to determine their reactions to diseases.
High-Throughput 4D TIMS Method Accelerates Lipidomics Analysis
April 25th 2024Ultrahigh-pressure liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) had been previously proposed for untargeted lipidomics analysis, but this updated approach was reported by the authors to reduce run time to 4 min.